T-DM1 offers better efficiency and a more favorable low-risk profile than capecitabine plus lapatinib, and T-DM1 is authorized to be used in individuals with trastuzumab plus a taxane-based prior therapy for metastatic HER2-positive breast cancer [23]. This evidence concerns the gene ERBB2 and breast cancer.